Brief: Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
03/03/2025 21:08
March 3 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL’S BLA SUBMISSIONS FOR TWO DENOSUMAB BIOSIMILARS ACCEPTED FOR REVIEW BY U.S. FDA AMNEAL PHARMACEUTICALS INC - FDA TARGET ACTION DATE FOR DENOSUMAB BIOSIMILARS IN Q4 2025 AMNEAL PHARMACEUTICALS INC - TO EXPAND TO SIX BIOSIMILARS BY 2027 AMNEAL PHARMA: THREE MORE BIOSIMILARS IN DEVELOPMENT Source text: ID:nBw2Kb0ZCa Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study